Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alternate Day Pomalidomide in Refractory Multiple Myeloma
NCT03520985Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2018
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
A Phase 2 trial of pomalidomide in multiple myeloma (MM), sponsored by Swiss Group for Clinical Cancer Research. Started Oct 2018; status: terminated.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03520985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520985.